



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Prophylactic Use of Haloperidol versus Atypical Antipsychotics (Quetiapine) in Prophylaxis against ICU Delirium in High Risk Patients

Thesis

*Submitted for partial fulfillment of Master Degree
In General Intensive Care*

By

Heba Ali Ahmed Abo Elkhair

M.B.CH.B (Menofia University)

Under Supervision of

Prof. Dr. Elham Abdul Latif Siam

*Professor of Anesthesia, Intensive care and Pain Management
Faculty of Medicine, Ain Shams University*

Dr. Sanaa Mohammed Al-Fawal

*Assistant Professor of Anesthesia, Intensive care and Pain Management
Faculty of Medicine, Ain Shams University*

Dr. Islam Abdel-Aal Abdel Muty Taher

*Lecturer of Anesthesia, Intensive Care and Pain Management
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, thanks to **ALLAH**, the most beneficent and merciful.*

*I wish to express my deepest appreciation and sincere gratitude to **Prof. Dr. Elham Abdul Latif Siam**, Prof. of Anesthesia, Intensive Care Medicine and Pain Management, Ain Shams University, for her supervision, continuous help and patience. It was a great honor for me to work under her supervision.*

*I wish to express my sincere thanks and deepest gratitude to **Dr. Sanaa Mohammed Al-Fawal**, Assistant Professor of anesthesia, intensive care medicine and pain management, Ain Shams University for her eminent guidance, encouragement and revision throughout the work.*

*Also, I would like to express my sincere thanks and deepest gratitude to **Dr. Islam Abdel-Aal Abdel Muty Taher**, lecturer of anesthesia, intensive care medicine and pain management, Ain Shams University, for his keen and valuable guidance and encouraging for applying some of these techniques.*

Finally, I would like to express my gratitude and deepest thanks to my family whom without their help and support, this work would not have been complete.

List of Contents

| Title | Page No. |
|--|----------|
| List of Tables | i |
| List of Figures | ii |
| List of Abbreviations..... | iii |
| Introduction | 1 |
| Aim of the Work..... | 4 |
| Review of Literature | |
| Delirium..... | 5 |
| Pharmacology of Haloperidol and Quetiapine | 34 |
| Patients and Methods..... | 56 |
| Results | 63 |
| Discussion | 72 |
| Conclusion | 84 |
| Summery | 85 |
| References | 89 |
| Arabic Summary | — |

List of Tables

| Table No. | Title | Page No. |
|--------------------|--|----------|
| Table (1): | Ramsay scale. | 14 |
| Table (2): | Sedation–agitation scale. | 14 |
| Table (3): | The Richmond agitation sedation Score. | 15 |
| Table (4): | Intensive Care Delirium Screening Checklist. | 17 |
| Table (5): | CAM-ICU. | 19 |
| Table (6): | APACHE II score. | 30 |
| Table (7): | Simpson-angus scale. | 47 |
| Table (8): | Demographic data of the studied groups | 63 |
| Table (9): | Comorbid conditions and drug abuse history. | 64 |
| Table (10): | Baseline clinical characters and severity assessed by APACH II score of the studied groups | 66 |
| Table (11): | Baseline laboratory data of the studied groups. | 68 |
| Table (12): | Assessment of RASS score in the studied groups. | 69 |
| Table (13): | Assessment of CAM score in the studied groups. | 70 |
| Table (14): | The frequency of side effects in the studied groups. | 71 |
| Table (15): | The final outcome of the studied groups. | 71 |

List of Figures

| Fig. No. | Title | Page No. |
|--------------------|---------------------------------|----------|
| Figure (1): | Pictures sheet of CAM-ICU. | 25 |

List of Abbreviations

| Abb. | Full term |
|----------------------|--|
| 5HT1A | Serotonin 5HT1A receptor antagonist. |
| APA..... | American Psychiatric Association. |
| APACHE II..... | The Acute physiology and chronic health evaluation II |
| APOE..... | apolipoprotein E. |
| ASE..... | Attention screening examination. |
| AUC | Area under the curve |
| CAM-ICU | Confusion Assessment Method for the ICU. |
| Cmax | Maximum or peak serum concentration that a drug achieves after has been administered and before administration of a second dose. |
| D1,2,3,4 receptor .. | Dopamine 1,2,3,4 receptor |
| DHF | decompensated heart failure. |
| DKA | Diabetic keto acidosis. |
| DRS..... | Delirium Rating Scale |
| DSM..... | Diagnostic and Statistical Manual of Mental Disorders. |
| ECG | Electrocardiography. |
| EEG | Electroencephalography. |
| EPS..... | Extrapyramidal symptoms |
| ER..... | Extended release. |
| GABA..... | γ -aminobutyric acid. |
| GCS..... | Glasgow coma score. |
| GnRH..... | Gonadotropin releasing hormone |
| H1receptor..... | Histamine 1 receptor antagonist |
| ICDSC | Intensive Care Delirium Screening Checklist |
| ICU | Intensive care unit |
| RCTS..... | Randomised Controlled Trials. |

List of Abbreviations Cont...

| Abb. | Full term |
|-----------------|---|
| IQR | Interquartile range |
| LAT1..... | Large neutral amino acid transporter type 1. |
| LOS..... | Length of stay. |
| MACH | Muscarinic acetylcholine receptor antagonist. |
| NMS..... | Neuroleptis malignant syndrome |
| PRE-DELIRIC.... | Prediction of Delirium in ICU patients. |
| RASS | Richmond Agitation-Sedation Scale. |
| RF | Respiratory failure. |
| SAS | Sedation-Agitation Scale |
| SCCM | Society of Critical Care Medicine. |
| T max..... | Time taken to reach maximum concentration |

INTRODUCTION

Delirium is defined as acute brain dysfunction featured by disturbances of attention, awareness and cognition with a fluctuating course caused by an underlying medical condition (*APA, 2013*), occurs frequently in the intensive care unit, is associated with impaired patient outcome, and substantially increases healthcare costs. Given these deleterious consequences, delirium prevention is crucial (*Salluh et al., 2015*).

The prevalence of delirium reported in medical and surgical ICU has varied from 20% to 80%, depending upon severity of illness observed and diagnostic methods used.

Mechanisms involved in the development of delirium, are thought related to neurotransmitters imbalances (an excess of dopamine or depletion of acetyl choline), inflammation and Impaired oxidative metabolism (*Ely et al., 2001*).

Multiple factors contribute to the development of delirium, including preexisting cognitive dysfunction, alcohol, drug withdrawal, sedative use, inadequate sleep, painful procedures, infection and shock state (*Ouimet et al., 2007*).

Delirium preventive measures are important for all ICU patients. However a delirium prediction model may facilitate early recognition of the patients who may benefit the most from delirium prevention. Non pharmacologic reduction strategies

and medication-based strategies may be most relevant for patients who have an increased risk of developing delirium (*Mistraletti et al., 2012*).

Various pharmacologic agents (such as Antipsychotics, acetylcholinesterase inhibitors, sleep-wake cycle regulators, and others) have been assessed for potential roles in delirium prevention (*Inouye, 2006*).

In this study Halopredol and Qutapiene used as preventive measures for prophylaxis of ICU delirium in high risk patients.

Halopridol is a typical antipsychotic medication. Halopridol is used in the treatment of schizophrenia, mania in bipolar disorder, delirium, agitation, acute psychosis and hallucinations in alcohol withdrawal. Despite limitations due to adverse events, including QT prolongation with the potential to trigger ventricular tachycardia, hypotension and extrapyramidal side effects (*Milbrandt et al., 2005*).

Quetiapine is an atypical antipsychotic drug used in treating schizophrenia, mania, depression and acute delirium outside the ICU (*Maze et al., 2001*).

Quetiapine like other anti-psychotics inhibits communication between nerves of the brain. It does this by blocking receptors on the nerves for neurotransmitters and chemicals that nerves use to communicate with each other. It is

thought that its beneficial effect is due to blocking of the dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptors so it is associated with lower ratings of agitation, shorter duration of delirium and Increased likelihood of discharge to home or rehabilitation (*Kim et al., 2003*).

Quetiapine has few extrapyramidal side effects or anticholinergic symptoms, a short half-life and is mildly sedating (*Kasliwal et al., 2010*).

AIM OF THE WORK

The aim of study is to compare the efficacy and safety of Quetiapine in prophylaxis against ICU delirium in high risk patient with that of haloperidol.